



Letter to the Editor

Predictors of strut coverage of drug eluting stent in diabetic patients – Is only on-clopidogrel platelet reactivity enough?



Jiamei Wang^{a,1}, Jianjiang Xu^{b,1}, Yihong Chen^{a,c,1}, Zhiqing He^a, Anna Hultgårdh-Nilsson^{d,*}, Chun Liang^{a,*}

^a Department of Cardiology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China

^b Department of Cardiology, Second Affiliated Hospital of Jiaxing University, Zhejiang, China

^c Department of Clinical Sciences, Lund University, Malmö, Sweden

^d Department of Experimental Medical Science, Lund University, Lund, Sweden

ARTICLE INFO

Article history:

Received 21 December 2018

Accepted 30 January 2019

Keywords:

Drug eluting stent

Diabetes

On-clopidogrel platelet reactivity

Editors,

We read with great interest the paper by Briguori et al. exploring whether uncovered strut rate in diabetic patients receiving drug eluting stent implantation could be predicted with on-clopidogrel platelet reactivity (OPR) and/or circulating endothelial progenitor cells (EPC), among which only the former and complex lesions were shown to be the independent predictors [1].

Nonetheless, we highlight a few important considerations about this study. First, only 36% participants' HbA_{1c} was less than 7%, which indicated the majority of the enrolled patients were far from meeting glycemic targets [2]. While better glycemic control was shown to be associated with elevated EPC numbers [3]. And in diabetic pathological conditions, the circulating EPCs might be in apoptotic and/or dysfunctional status, which could not be simply evaluated by EPC levels. Second, circulating EPCs, a heterogeneous population of cells characterized by the expression of several surface antigens, include hematopoietic and non-hematopoietic ones [4]. The latter of which could differentiate into adherent endothelial cells and express different surface antigen patterns. So combination of CD34 and CD309 might lead to biased estimates of bona fide circulating EPC levels.

The results of the current study pointed out OPR as a predictor for uncovered strut rate in high-risk patients receiving DES implementation, while the potential role of putative EPCs especially their status and activity might be neglected, which demands furthermore research.

Acknowledgement

Declaration of personal interests

None.

Funding information

This work was supported by NSFC grants (91539118, 81611130092) to C.L., 17XD1405000, ZY(2018-2020)-FWTX-1102 and LJRC2015-21 to C.L., and CSC (201703170134) to Y.C.

References

- [1] C. Briguori, C. Quintavalle, M. Donahue, F. D'Alessio, C. D'Amore, G. Signoriello, L. Del Vecchio, R. De Caterina, G. Condorelli, Predictors of strut coverage of drug eluting stent implantation in diabetic patients, *Int. J. Cardiol.* 276 (2019) 61–65.
- [2] M.J. Davies, D.A. D'Alessio, J. Fradkin, W.N. Kernan, C. Mathieu, G. Mingrone, P. Rossing, A. Tsapas, D.J. Wexler, J.B. Buse, Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), *Diabetologia* 61 (2018) 2461–2498.
- [3] T. Hortenhuber, B. Rami-Mehar, M. Satler, K. Nagl, C. Hobaus, F. Hollerl, R. Koppensteiner, G. Scherthaner, E. Schober, G.H. Scherthaner, Endothelial progenitor cells are related to glycemic control in children with type 1 diabetes over time, *Diabetes Care* 36 (2013) 1647–1653.
- [4] M.S. Chong, W.K. Ng, J.K. Chan, Concise review: endothelial progenitor cells in regenerative medicine: applications and challenges, *Stem Cells Transl. Med.* 5 (2016) 530–538.

* Corresponding authors.

E-mail addresses: anna.hultgardh@med.lu.se (A. Hultgårdh-Nilsson), chunliang@smmu.edu.cn (C. Liang).

¹ Jiamei Wang, Jianjiang Xu, and Yihong Chen contribute equal to the manuscript and should be considered as the combined first author.